Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD25 antibody-drug conjugate PF-08046032

An antibody-drug conjugate (ADC) composed of a detuned-affinity monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CD25 ADC PF-08046032 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in the Treg cells. This depletes Treg cells in the tumor microenvironment (TME) and prevents immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the IL-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC PF-08046032
anti-CD25 ADC PF-08046032
anti-CD25/MMAE ADC PF-08046032
Code name:PF 08046032
PF-08046032
PF08046032
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search